Functional and structural characteristics in patients with type 3 macular neovascularisation treated with anti-VEGF. Three-year results in real world settings.
Journal
Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986
Informations de publication
Date de publication:
06 Jan 2024
06 Jan 2024
Historique:
received:
14
05
2023
accepted:
20
12
2023
revised:
09
12
2023
medline:
7
1
2024
pubmed:
7
1
2024
entrez:
6
1
2024
Statut:
aheadofprint
Résumé
To evaluate the long-term anatomical and functional outcomes of anti-Vascular Endothelial Growth Factor intravitreal injections (anti-VEGF IVI) in patients with type 3 macular neovascularisation (MNV) in real-world settings. Retrospective review of patients with type 3 MNV who received anti-VEGF IVI between 2013 and 2020. Primary outcomes were best corrected visual acuity (BCVA) and central macular thickness (CMT). Secondary outcome was the development of new-onset of foveal-involving geographic atrophy (GA) and disciform scars. We identified 59 eyes from 48 British patients that met the inclusion criteria. Treatment with anti- VEGF IVI resulted in a statistically significant reduction in median CMT, which was maintained throughout the study period. At 36 months, 24 eyes showed more than 50 μm reduction in CMT, 7 eyes remained stable and only 2 eyes showed an increase in CMT by more than 50μm compared to the baseline. At year three, deterioration was noticed in most eyes (52.78%) and vision remained stable or improved in 47.22% of the eyes. However, the median BCVA was not statistically significant different compared to baseline. During the study period new onset of macula-involving atrophy or scar was noted in 10.2% and 4.3% of the eyes, respectively. In this real-world study, anatomic and functional improvement were recorded 12-months post anti-VEGF IVI in type 3 MNV. Despite sustained anatomical improvement, vision returned back to baseline levels at 36-months. The development of GA and macular scar was only partially responsible for this outcome suggesting a more severe nature of this form of nAMD.
Sections du résumé
BACKGROUND
BACKGROUND
To evaluate the long-term anatomical and functional outcomes of anti-Vascular Endothelial Growth Factor intravitreal injections (anti-VEGF IVI) in patients with type 3 macular neovascularisation (MNV) in real-world settings.
METHODS
METHODS
Retrospective review of patients with type 3 MNV who received anti-VEGF IVI between 2013 and 2020. Primary outcomes were best corrected visual acuity (BCVA) and central macular thickness (CMT). Secondary outcome was the development of new-onset of foveal-involving geographic atrophy (GA) and disciform scars.
RESULTS
RESULTS
We identified 59 eyes from 48 British patients that met the inclusion criteria. Treatment with anti- VEGF IVI resulted in a statistically significant reduction in median CMT, which was maintained throughout the study period. At 36 months, 24 eyes showed more than 50 μm reduction in CMT, 7 eyes remained stable and only 2 eyes showed an increase in CMT by more than 50μm compared to the baseline. At year three, deterioration was noticed in most eyes (52.78%) and vision remained stable or improved in 47.22% of the eyes. However, the median BCVA was not statistically significant different compared to baseline. During the study period new onset of macula-involving atrophy or scar was noted in 10.2% and 4.3% of the eyes, respectively.
CONCLUSION
CONCLUSIONS
In this real-world study, anatomic and functional improvement were recorded 12-months post anti-VEGF IVI in type 3 MNV. Despite sustained anatomical improvement, vision returned back to baseline levels at 36-months. The development of GA and macular scar was only partially responsible for this outcome suggesting a more severe nature of this form of nAMD.
Identifiants
pubmed: 38184726
doi: 10.1038/s41433-023-02918-w
pii: 10.1038/s41433-023-02918-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.
Références
Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, et al. Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology. 2020;127:616–36.
doi: 10.1016/j.ophtha.2019.11.004
pubmed: 31864668
Slakter JS, Yannuzzi LA, Schneider U, Sorenson JA, Ciardella A, Guyer DR, et al. Retinal choroidal anastomoses and occult choroidal neovascularization in age-related macular degeneration. Ophthalmology. 2000;107:742–53. discussion 753-4
doi: 10.1016/S0161-6420(00)00009-9
pubmed: 10768338
Yannuzzi LA, Negrão S, Iida T, Carvalho C, Rodriguez-Coleman H, Slakter J, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina. 2001;21:416–34.
doi: 10.1097/00006982-200110000-00003
pubmed: 11642370
Krebs I, Stolba U, Glittenberg C, Seyeddain O, Benesch T, Binder S. Prognosis of untreated occult choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2007;245:376–84.
doi: 10.1007/s00417-006-0424-1
pubmed: 17072636
Cohen SY, Creuzot-Garcher C, Darmon J, Desmettre T, Korobelnik JF, Levrat F, et al. Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degeneration. Br J Ophthalmol. 2007;91:1173–6.
doi: 10.1136/bjo.2007.115501
pubmed: 17383997
pmcid: 1954889
Kim JH, Chang YS, Kim JW, Kim CG, Lee DW. Age-related differences in the prevalence of subtypes of Neovascular age-related macular degeneration in the first diagnosed eye. Graefes Arch Clin Exp Ophthalmol. 2019;257:891–8.
doi: 10.1007/s00417-018-04228-4
pubmed: 30617580
Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol. 2007;144:15–22.
doi: 10.1016/j.ajo.2007.03.047
pubmed: 17509509
Freund KB, Ho IV, Barbazetto IA, Koizumi H, Laud K, Ferrara D, et al. Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation. Retina. 2008;28:201–11.
doi: 10.1097/IAE.0b013e3181669504
pubmed: 18301024
Viola F, Massacesi A, Orzalesi N, Ratiglia R, Staurenghi G. Retinal angiomatous proliferation: natural history and progression of visual loss. Retina. 2009;29:732–9.
doi: 10.1097/IAE.0b013e3181a395cb
pubmed: 19516115
Ghazi NG, Knape RM, Kirk TQ, Tiedeman JS, Conway BP. Intravitreal bevacizumab (avastin) treatment of retinal angiomatous proliferation. Retina. 2008y;28:689–95.
doi: 10.1097/IAE.0b013e318162d982
pubmed: 18463511
Meyerle CB, Freund KB, Iturralde D, Spaide RF, Sorenson JA, Slakter JS, et al. Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation. Retina. 2007;27:451–7.
doi: 10.1097/IAE.0b013e318030ea80
pubmed: 17420697
Joeres S, Heussen FMA, Treziak T, Bopp S, Joussen AM. Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol. 2007;245:1597–602.
doi: 10.1007/s00417-007-0580-y
pubmed: 17437123
Gharbiya M, Allievi F, Recupero V, Martini D, Mazzeo L, Gabrieli CB. Intravitreal bevacizumab as primary treatment for retinal angiomatous proliferation: twelve-month results. Retina. 2009;29:740–9.
doi: 10.1097/IAE.0b013e3181a0be1d
pubmed: 19516116
Lai TYY, Chan WM, Liu DT, Lam DS. Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2007;245:1877–80.
doi: 10.1007/s00417-007-0679-1
pubmed: 17901972
Konstantinidis L, Mameletzi E, Mantel I, Pournaras JA, Zografos L, Ambresin A. Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP). Graefes Arch Clin Exp Ophthalmol. 2009;247:1165–71.
doi: 10.1007/s00417-009-1089-3
pubmed: 19404661
Invernizzi A, Teo K, Nguyen V, Daniell M, Squirrell D, Barthelmes D, et al. Type 3 neovascularisation (retinal angiomatous proliferation) treated with antivascular endothelial growth factor: real-world outcomes at 24 months. Br J Ophthalmol. 2019;103:1337–41.
doi: 10.1136/bjophthalmol-2018-312944
pubmed: 30504490
Huang YY, Lo WJ, Chang HY, Chou YB, Lin TC. Three-Year Outcomes of Intravitreal Aflibercept Injections for Retinal Angiomatous Proliferation According to Disease Stage. Ophthalmol Ther. 2022;11:1503–16.
doi: 10.1007/s40123-022-00521-y
pubmed: 35596037
pmcid: 9253227
Daniel E, Shaffer J, Ying Gshuang, Grunwald JE, Martin DF, Jaffe GJ, et al. Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Ophthalmology. 2016;123:609–16.
doi: 10.1016/j.ophtha.2015.10.034
pubmed: 26681392
Cho HJ, Yoo SG, Kim HS, Kim JH, Kim CG, Lee TG, et al. Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation. Am J Ophthalmol. 2015;159:285–.e1.
doi: 10.1016/j.ajo.2014.10.035
pubmed: 25447115
Foss A, Rotsos T, Empeslidis T, Chong V. Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment. Ophthalmologica. 2022;245:204–17.
doi: 10.1159/000520171
pubmed: 34695835
Costagliola C, Romano MR, dell’Omo R, Cipollone U, Polisena P. Intravitreal bevacizumab for the treatment of retinal angiomatous proliferation. Am J Ophthalmol. 2007;144:449–51.
doi: 10.1016/j.ajo.2007.05.025
pubmed: 17765426
Montero JA, Fernandez MI, Gomez-Ulla F, Ruiz-Moreno JM. Efficacy of intravitreal bevacizumab to treat retinal angiomatous proliferation stage II and III. Eur J Ophthalmol. 2009;19:448–51.
doi: 10.1177/112067210901900320
pubmed: 19396793
Atmani K, Voigt M, Le Tien V, Querques G, Coscas G, Soubrane G, et al. Ranibizumab for retinal angiomatous proliferation in age-related macular degeneration. Eye. 2010;24:1193–8.
doi: 10.1038/eye.2010.9
pubmed: 20150927
Parodi MB, Iacono P, Menchini F, Sheth S, Polini G, Pittino R, et al. Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation. Acta Ophthalmol. 2013;91:267–73.
doi: 10.1111/j.1755-3768.2011.02265.x
pubmed: 21951313
Reche-Frutos J, Calvo-Gonzalez C, Pérez-Trigo S, Fernandez-Perez C, Donate-Lopez J, Garcia-Feijoo J. Ranibizumab in retinal angiomatous proliferation (RAP): influence of RAP stage on visual outcome. Eur J Ophthalmol. 2011;21:783–8.
doi: 10.5301/EJO.2011.6526
pubmed: 21484755
Gharbiya M, Parisi F, Cruciani F, Bozzoni-Pantaleoni F, Pranno F, Abdolrahimzadeh S. Intravitreal anti-vascular endothelial growth factor for retinal angiomatous proliferation in treatment-naive eyes: long-term functional and anatomical results using a modified PrONTO-style regimen. Retina. 2014;34:298–305.
doi: 10.1097/IAE.0b013e3182979e62
pubmed: 23807188
Tsaousis KT, Konidaris VE, Banerjee S, Empeslidis T. Intravitreal aflibercept treatment of retinal angiomatous proliferation: a pilot study and short-term efficacy. Graefes Arch Clin Exp Ophthalmol. 2015;253:663–5.
doi: 10.1007/s00417-014-2835-8
pubmed: 25338279
Park YG, Roh YJ. One year results of intravitreal ranibizumab monotherapy for retinal angiomatous proliferation: a comparative analysis based on disease stages. BMC Ophthalmol. 2015;15:182.
doi: 10.1186/s12886-015-0172-2
pubmed: 26691185
pmcid: 4685625
Chou HD, Wu WC, Wang NK, Chuang LH, Chen KJ, Lai CC. Short-term efficacy of intravitreal Aflibercept injections for retinal angiomatous proliferation. BMC Ophthalmol. 2017;17:104.
doi: 10.1186/s12886-017-0497-0
pubmed: 28655307
pmcid: 5488380
Ernest J, Manethova K, Kolar P, Sobisek L, Sacconi R, Querques G. One-Year Results of Fixed Aflibercept Treatment Regime in Type 3 Neovascularization. Ophthalmologica. 2020;243:58–65.
doi: 10.1159/000499719
pubmed: 31121590
Browning AC, O’Brien JM, Vieira RV, Gupta R, Nenova K. Intravitreal Aflibercept for Retinal Angiomatous Proliferation: Results of a Prospective Case Series at 96 Weeks. Ophthalmologica. 2019;242:239–46.
doi: 10.1159/000500203
pubmed: 31163436
De Salvo G, Hannan SR, James N, Lotery AJ. Retinal angiomatous proliferation occurring after radiotherapy. Eye. 2013;27:447–9.
doi: 10.1038/eye.2012.274
pubmed: 23288139
pmcid: 3597878
Cho HJ, Lee TG, Han SY, Kim HS, Kim JH, Han JI, et al. Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol. 2016;254:23–30.
doi: 10.1007/s00417-015-2993-3
pubmed: 25825231
Gross NE, Aizman A, Brucker A, Klancnik JMJ, Yannuzzi LA. Nature and risk of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. Retina. 2005;25:713–8.
doi: 10.1097/00006982-200509000-00005
pubmed: 16141858
Jaffe GJ, Ying GS, Toth CA, Daniel E, Grunwald JE, Martin DF, et al. Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology. 2019;126:252–60.
doi: 10.1016/j.ophtha.2018.08.035
pubmed: 30189282
Campa C, Harding SP, Pearce IA, Beare NAV, Briggs MC, Heimann H. Incidence of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. Eye. 2010;24:1585–9.
doi: 10.1038/eye.2010.88
pubmed: 20539314
Rabiolo A, Sacconi R, Cicinelli MV, Querques L, Bandello F, Querques G. Spotlight on reticular pseudodrusen. Clin Ophthalmol. 2017;11:1707–18.
doi: 10.2147/OPTH.S130165
pubmed: 29033536
pmcid: 5614782
Borrelli E, Souied EH, Freund KB, Querques G, Miere A, Gal-Or O, et al. Reduced choriocapillaris flow in Eyes with type 3 Neovascularization and age-related macular degeneration. Retina. 2018;38:1968–76.
doi: 10.1097/IAE.0000000000002198
pubmed: 29746411
Baek J, Lee JH, Kim JY, Kim NH, Lee WK. Geographic Atrophy and Activity of Neovascularization in Retinal Angiomatous Proliferation. Invest Ophthalmol Vis Sci. 2016;57:1500–5.
doi: 10.1167/iovs.15-18837
pubmed: 27031843
Sacconi R, Sarraf D, Sadda SR, Freund KB, Servillo A, Fogel Levin MM, et al. Nascent Geographic Atrophy as a Predictor of Type 3 Macular Neovascularization Development. Ophthalmol Retina. 2023;7:586–92.